About Us


Deprecated: Function wp_make_content_images_responsive is deprecated since version 5.5.0! Use wp_filter_content_tags() instead. in /home/emergence_tx/releases/20201126141642Z/web/wp/wp-includes/functions.php on line 5383

Emergence Therapeutics is a European biopharmaceutical company developing novel antibody drug conjugate (ADC) therapeutics to treat high need cancers. Our lead program features innovative antibody design as well as state of the art linker and payload technology to target Nectin-4 – an important and validated target for a broad range of cancers. This approach brings the promise of superiority to enfortumab vedotin, a high-profile ADC for urothelial cancer.

We are also developing a broader pipeline of additional first- or best-in-class ADCs driven by therapeutic need.

Emergence is led by a strong management team supported by a network of world-leading experts and leading international investors.

Management
Team

Dr. Jack Elands
Chief Executive Officer
Carsten Dehning
Chief Financial Officer
Dr. Xavier Preville
Chief Scientific Officer
Dr. Florence Lhospice
Chief Development Officer
Dr. Hatem Azim
Chief Medical Officer

Supervisory
Board

Irina Staatz
Chairperson of the Supervisory Board
Peter Neubeck
Deputy Chairman of the Supervisory Board
Roy Amariglio
Member of the Supervisory Board
Ohad Hammer
Member of the Supervisory Board
Matthew Hammond
Member of the Supervisory Board
Olivier Martinez
Member of the Supervisory Board
Anke Cassing
Observer
Roger Franklin
Observer
Marek Kozlowski
Observer
Thierry Laugel
Observer

Scientific
Advisory Board

Xavier Preville
Chairman
Rakesh Dixit
Advisor
Robert Lutz
Advisor
John Lambert
Advisor
François Romagné
Advisor & Collaborator
Marc Lopez
Advisor & Collaborator
Daniel Olive
Advisor & Collaborator